Molecular imaging modalities are used for different type of cancers detection and diagnosis. In recent few years, there has been an increased focus on developing novel nanoparticles as new imaging contrast agents for early detection of cancer. The aim of this review article is to summarize molecular imaging technologies accompanying with using nanoparticles to improve potential imaging for cancer detection and hence valuable therapy in the future.Nanoprobes are rapidly becoming potentially transformative tools on cancer diagnostics for a wide range of imaging modalities such as CT, MRI, SPECT, PET, Ultrasound and Optical imaging. The study results seen in the recent literature are provided and discussed the diagnostic performance of imaging modalities for cancer diagnosis and their future directions.With knowledge of the correlation between the application of nanoparticles and molecular imaging modalities and with the development of targeted contrast agents or nanoprobes, they may provide better cancer diagnosis in the future.
#1008 Background: Touch imprint cytology (TIC) as a tool for intra-operative assessment of sentinel lymph nodes (SLN) in breast cancer has been shown to be rapid, reliable and cost-effective. Its use in lobular cancer is however more challenging due to the pattern of lymph node infiltration, smaller cells, similarity to lymphocytes and low grade cytomorphology. The aim of this study was to evaluate the sensitivity and specificity of intra-operative TIC in assessing SLN metastases in patients with lobular breast cancer.
 Material and Methods: All patients with lobular carcinoma who underwent intra-operative TIC assessment of the SLN were identified within our prospectively collected database. The SLN was bi-valved along its longitudinal axis and imprinted onto a slide at least six times before air-drying. The slide was treated with the rapid Giemsa stain before examination by one of three cytopathologists. Where TIC revealed SLN metastases, the patient underwent immediate axillary clearance. The SLN were then processed for histopathology by sectioning at three levels before haematoxylin and eosin staining. Those lymph nodes found to be negative then underwent immunocytohistochemistry staining before being declared truly negative. All patients with SLN metastases not identified during surgery received a delayed axillary clearance. The TIC results were compared to the final histopathology result of the SLN and the sensitivity and specificity calculated.
 Results: 51 patients with lobular cancer who underwent TIC were identified. The table below summarises the results:
 
 The sensitivity thus calculated was 76.0%; the specificity 100.0% and the negative predictive value 81.25%. Of the 6 false negative cases, 4 were grade 1 and 2 were grade 2. The mean primary tumour size in this group was 17mm (range 11 to 27mm). In all 6 cases, axillary metastases was found in 3 or fewer lymph nodes post axillary clearance.
 Discussion: This study demonstrates the reliability of using intra-operative TIC to evaluate SLN during surgery for lobular cancer. It compares very favourably to data published in the literature from other institutions that have examined the use of TIC in lobular carcinoma and may relate to the presence of experienced, highly motivated cytopathologists at our unit. In addition, it also compares well with other studies describing the use of TIC in ductal carcinoma, including our own unit's previously published data. Thus, in experienced hands, TIC is feasible with an acceptable accuracy allowing intra-operative SLN assessment in patients with lobular breast cancer. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1008.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.